The Janssen Pharmaceutical Companies announced they have submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for approval of a single tablet combination of 10 mg of macitentan and 40 mg of tadalafil (M/T STCT) to treat patients with pulmonary arterial hypertension (PAH). “People with PAH are often prescribed numerous…
Nobiletin has been found to attenuate monocrotaline-induced pulmonary arterial hypertension (PAH) conditions in rat models; these results indicate that it may inhibit PAH-related inflammation through the PI3K/AKT/STAT3 pathway, according to a study published in the Journal of Pharmacy and Pharmacology. A growing number of studies have implicated inflammation as a key driver of PAH pathology.…
In patients with pulmonary arterial hypertension (PAH), zinc homeostasis plays a key protective role in the pathogenesis of the disease. Thus, regulation of metal responsive transcription factor 1 (MTF-1)—a zinc-dependent transcription factor—may be a potential target for therapeutic intervention in PAH, according to findings from a study published in the journal Cell Cycle. Individuals with…
A new study has found that despite a sustained response to calcium channel blockers (CCBs), patients with idiopathic pulmonary arterial hypertension (PAH) can lose their response and require further targeted therapies. The study, published in the Journal Brasileiro de Pneumologia, highlights the need for continual, multidimensional re-evaluation in these patients even when they respond well…
Supervised and unsupervised learning algorithms may improve risk assessment and clinical phenotyping in pulmonary arterial hypertension (PAH), according to a long-term retrospective observational study published in BMC Pulmonary Medicine. “In this proof of concept study, we demonstrate the usefulness of supervised multi-parameter Elastic Net survival modeling and unsupervised PAM [partition around medoids] clustering for search…
A new study has determined that in a rat model of pulmonary arterial hypertension (PAH), remodeling of ion channel, calcium-handling, and fibrosis genes leads to sinus node dysfunction and subsequent arrhythmias. The study, published in Philosophical Transactions of the Royal Society B, observed a decrease in the intrinsic pacemaker activities in the sinus node late…
In individuals with pulmonary arterial hypertension (PAH), insulin-like growth factor binding protein 4 (IGFBP4) is a potential new circulating biomarker that is linked to disease severity and patient survival, according to findings from a cohort analysis published in Pulmonary Circulation. With the emergence of symptoms associated with PAH frequently presenting later on in the disease…
Specific metabolite profiles may reveal right ventricular (RV) functional measurements of people with pulmonary arterial hypertension (PAH) as accurately as invasive pressure-volume loop analysis, as well as predict RV response to exercise, according to an article published in the American Journal of Physiology-Lung Cellular and Molecular Physiology. For this study, the researchers recruited 23 patients…
Using US claims-based predictive models, a team of researchers demonstrated that 1-year hospitalization rates among patients with pulmonary arterial hypertension (PAH) remains at acceptable levels, according to a study published in Advances in Therapy. PAH is frequently associated with hospitalizations, especially as the disease progresses. Studies indicate that over 50% of patients newly diagnosed with…
A new prospective, multicenter, open-label clinical trial will evaluate early and rapid treprostinil afterload-lowering therapy as a potential disease-modifying treatment option for pulmonary arterial hypertension (PAH). The new trial, known as ARTISAN (afterload reduction to improve right ventricular structure and function), will enroll approximately 50 subjects with confirmed PAH who are PAH treatment naive or…
Please login or register first to view this content.
